Treatment with upadacitinib yielded improvements in pain and function and reduced radiographic progression over 2 years among the study cohort. Researchers assessed the 2-year efficacy and safety ...

Treatment with upadacitinib yielded improvements in pain and function and reduced radiographic progression over 2 years among the study cohort. Researchers assessed the 2-year efficacy and safety of ...

MONDAY, Dec. 23, 2024 (HealthDay News) -- For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib ...